Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $24.50 Average PT from Analysts

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been assigned an average rating of “Reduce” from the eight brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $24.50.

Several brokerages recently commented on AMPH. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 11th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $19.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Barclays cut their price objective on Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating for the company in a report on Wednesday, April 8th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new position in Amphastar Pharmaceuticals during the third quarter valued at $26,000. Quarry LP purchased a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at about $32,000. Farther Finance Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after acquiring an additional 437 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Amphastar Pharmaceuticals by 37.8% in the fourth quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after acquiring an additional 462 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Down 2.3%

Amphastar Pharmaceuticals stock opened at $18.42 on Thursday. The firm has a market cap of $812.19 million, a price-to-earnings ratio of 11.10, a PEG ratio of 3.71 and a beta of 0.97. The stock has a fifty day simple moving average of $20.08 and a two-hundred day simple moving average of $23.79. Amphastar Pharmaceuticals has a 12 month low of $16.65 and a 12 month high of $31.26. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.The business had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. Equities analysts predict that Amphastar Pharmaceuticals will post 2.41 EPS for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.